<DOC>
	<DOCNO>NCT02288195</DOCNO>
	<brief_summary>Although neoadjuvant radiotherapy greatly decrease local recurrence locally advanced rectal cancer patient undergo surgery , inevitably result short-term long-term toxicity . More importantly , confirm neoadjuvant radiotherapy could improve overall survival . The purpose study compare effect chemotherapy alone use combination regimen know XELOX ( capecitabine oxaliplatin ) selective use standard treatment standard treatment chemotherapy radiation .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation Locally Advanced Rectal Cancer Patients</brief_title>
	<detailed_description>This randomise , open-label , multicentre , phase 3 trial begin August , 2014 , adjuvant trial compare capecitabine-based neoadjuvant chemoradiotherapy chemotherapy alone , patient age 18 year 75 clinical stage II-III locally advance rectal cancer six Chinese institution . Patients local advanced rectal cancer ( T2N+ T3-4aNany , M0 , CRM≥2mm , 5-12cm anus ) schedule Group A : receive neoadjuvant chemotherapy alone ( 4 cycle XELOX : oxaliplatin 130mg/m2 day 1，capecitabine 2000mg/m2 day 1-14 , repeat every 21 day ) follow radical surgery 4 cycle XELOX ( oxaliplatin 130mg/m2 day 1，capecitabine 2000mg/m2 day 1-14 , repeat every 21 day ) Group B : chemoradiotherapy ( 50.4 Gy plus capecitabine 1650 mg/m² administer orally concurrently radiation therapy 5 day per week . ) follow radical surgery 6 cycle XELOX ( oxaliplatin 130mg/m2 day 1，capecitabine 2000mg/m2 day 1-14 , repeat every 21 day ) The primary endpoint overall survival ; analyse do base patient post-randomization data .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis rectal adenocarcinoma Radiologically measurable clinically evaluable disease Tumor location 512cm anal verge Clinical stage T2N+ T34aNany , M0 Clinical stag estimate base combination follow assessment : physical examination primary surgeon , CT scan chest/abdomen/pelvis , pelvic MRI without endorectal ultrasound ( ERUS ) No evidence tumor adjacent ( define within 2 mm ) mesorectal fascia preoperative MRI No tumor cause symptomatic bowel obstruction No distant metastasis PATIENT CHARACTERISTICS : ECOG performance status 0 , 1 White Blood Cell ( WBC ) ≥ 4,000/mm³ Platelets ≥ 100,000/mm³ Hemoglobin &gt; 10.0 g/dL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 1.5 time ULN Creatinine ≤ 1.5 time ULN No comorbid illnesses concurrent disease , judgment clinician obtain informed consent , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimens Pregnant nursing Patient childbearing potential willing employ adequate contraception Not willing return enrol medical site study assessment With invasive malignancy ≤ 5 year prior registration ; exception colonic polyp , nonmelanoma skin cancer , carcinomainsitu cervix Chemotherapy within 5 year prior registration ( hormonal therapy allowable diseasefree interval ≥ 5 year ) Prior pelvic radiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Neoadjuvant Chemotherapy</keyword>
	<keyword>Preoperative radiotherapy</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Oxaliplatin</keyword>
</DOC>